Skip to main content
. 2023 May 2;9(5):e15693. doi: 10.1016/j.heliyon.2023.e15693

Fig. 6.

Fig. 6

Investigation of the therapeutic response between molecular clusters. A. Differences of immunophenoscore of PD1, CTLA4 and PD1+CTLA4 blockades between the molecular clusters. B. Differences of IC50 of Axitinib, Pazopanib, Sorafenib, and Sunitinib among the molecular clusters. C-D. Patients in cluster A responded better to modulation of TGFβ and IFNγ signaling pathways than those in cluster B. E. Difference of 10 oncogenic pathways among cluster A and B.